Mural Oncology PLC (MURA) News

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data...

Mural Oncology to Participate in Two Upcoming Investor Conferences

WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a...

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian...

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a...

Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a...

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a...

Form 8-K - Current report

Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress

Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected...

Form 8-K - Current report

Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a...